Specifically, inhibitiong heat-shock proteins (HSP), namely HSP90, a chaperone protein that stabilizes a wide variety of proteins, including ALK, has shown some preclinical efficacy in crizotinib-resistant ALK fusions (EML4-ALK and NPM1-ALK), including secondary resistant mutants in lung cancer models [67]. This evidence concerns the gene NPM1 and lung carcinoma.